Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 9/20 | 0.38 |
| ▸ | CA1 | P00915 | 8/20 | 0.38 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16006895 | 1.00 | MAOA (0.46) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL4589365 | 0.98 | MAOA (0.47) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL23571295 | 0.88 | MAOA (0.53) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL34362 | 0.85 | TDP1 (0.58) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL30099494 | 0.85 | MAOA (0.49) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL16380027 | 0.84 | TDP1 (0.46) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL20470254 | 0.84 | TDP1 (0.54) | MAOAMAOBTDP1MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28173213 | 0.83 | TDP1 (0.56) | MAOAMAOBTDP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL219905 | 0.83 | TDP1 (0.56) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL21549666 | 0.83 | TDP1 (0.49) | MAOAMAOBTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3965891-A1 | ANTIBODY DRUG CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020229982-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | MAOA 2492/4885MAOB 2648/4885TDP1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.